This content is only available for ASCRS Members
This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
Filed Under
Presbyopia
presbyopia-correcting IOL
Fuchs' endothelial dystrophy
Fuchs' dystrophy
presbyopia correction
2020 paper presentation
Purpose
To report the results of presbyopia-correcting intraocular lenses (IOLs) implantation in patients with Fuchs endothelial corneal dystrophy (FECD).
Methods
A retrospective, case-control study of FECD patients that were implanted with presbyopia-correcting IOLs. The results were compared with a matched group of patients at a case-control ratio of 1:3. Endothelial cell count, uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA) and post-operative refraction were analyzed.
Results
A total of 19 eyes of 10 patients with FECD were included in the study (mean endothelial cell count 1323.52±767.54 cells/mm2). No significant difference between FECD patients and the control group were found in the UCDVA (LogMAR) (mean 0.11±0.13 and 0.06±0.10, P=0.12, respectively), UCIVA (LogMAR) (mean 0.11±0.11 and 0.10±0.12, P=0.98, respectively) and post-operative refraction outcomes (mean spherical equivalent (SE) (D) 0.14±0.31 and -0.21±0.24, P=0.31, respectively).The UCNVA (LogMAR) was better among the FECD patients, 0.03±0.05 compared to 0.15±0.18 in the control group (P=0.009).
Conclusion
Our results suggest that presbyopia-correcting IOLs can be considered in patients with FECD, with clear corneas, that are not candidate for corneal transplantation.
To report the results of presbyopia-correcting intraocular lenses (IOLs) implantation in patients with Fuchs endothelial corneal dystrophy (FECD).
Methods
A retrospective, case-control study of FECD patients that were implanted with presbyopia-correcting IOLs. The results were compared with a matched group of patients at a case-control ratio of 1:3. Endothelial cell count, uncorrected distance visual acuity (UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA) and post-operative refraction were analyzed.
Results
A total of 19 eyes of 10 patients with FECD were included in the study (mean endothelial cell count 1323.52±767.54 cells/mm2). No significant difference between FECD patients and the control group were found in the UCDVA (LogMAR) (mean 0.11±0.13 and 0.06±0.10, P=0.12, respectively), UCIVA (LogMAR) (mean 0.11±0.11 and 0.10±0.12, P=0.98, respectively) and post-operative refraction outcomes (mean spherical equivalent (SE) (D) 0.14±0.31 and -0.21±0.24, P=0.31, respectively).The UCNVA (LogMAR) was better among the FECD patients, 0.03±0.05 compared to 0.15±0.18 in the control group (P=0.009).
Conclusion
Our results suggest that presbyopia-correcting IOLs can be considered in patients with FECD, with clear corneas, that are not candidate for corneal transplantation.
View More Presentations from this Session
This presentation is from the session "SPS-107 Presbyopia Correction II" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.